68449-32-1

Usage

Uses

Used in Pharmaceutical Synthesis:
8-CHLORO-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE is used as a key intermediate in the development of pharmaceuticals for its ability to contribute to the formation of complex organic molecules that possess therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 8-CHLORO-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE is utilized as a precursor in the synthesis of various agrochemicals, playing a crucial role in the development of compounds that protect crops and enhance agricultural productivity.
Used in Fragrance and Flavoring Industry:
8-CHLORO-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE is employed as a building block in the creation of fragrances and flavorings, capitalizing on its chemical structure to produce desirable scents and tastes for consumer products.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 8-CHLORO-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE is instrumental in the production of a range of organic compounds, serving as a fundamental component in various chemical reactions.
Used in Material Science and Research:
8-CHLORO-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE may also be applied in material science for the development of new materials, as well as in research activities where its unique properties can be explored for novel applications.

InChI:InChI=1/C10H9ClO/c11-8-5-1-3-7-4-2-6-9(12)10(7)8/h1,3,5H,2,4,6H2

Upstream product

• 2217-41-6 1-amino-5,6,7,8-tetrahydronaphthalene 
• 110139-15-6 N-(8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 6272-18-0 N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 210346-49-9 8-aminotetralone 
• 104354-39-4 3,4-dihydro-naphthalen-1(2H)-one oxime O-methyl ether 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 1310699-69-4 9-chloro-1,3,4,5-tetrahydro-2H-1-benzoazepin-2-one 
• 1310699-86-5 2-(9-chloro-2-oxo-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)-N-[(1S)-1-phenylethyl]acetamide 
• 1310700-91-4 methyl (2-oxo-9-phenyl-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)acetate 
• 1310699-75-2 9-phenyl-1,3,4,5-tetrahydro-2H-1-benzoazepin-2-one 

Relevant academic research and scientific papers

INHINITORS OF GLI1 AS THERAPEUTIC AGENTS

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma- associated oncogene (Gli) expression. More particularly, this disclosure relate

NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R1, R2, R3, R4, R5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

CARBAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES

The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a carbamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention CNS disorders comprising administering a carbamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of CNS disorders.

CYCLIC COMPOUNDS

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF????

Disclosed are compounds of Formula (I), pharmaceutical compositions comprising the same, processes for the preparation thereof, and the use thereof.

Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands

A series of N-substituted analogs based upon the spiropiperidine core of 1 was synthesized and exhibited high binding affinity to the nociceptin (NOP) receptor. The selectivities against other known opioid receptors were determined.

A Convenient Synthesis of 7-Halo-1-indanones and 8-Halo-1-tetralones

A regioselective oxidation of N-indan-4-yl-acetamide or N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide with potassium permanganate followed by acidic hydrolysis gave 7-aminoindan-1-one or 8-aminotetral-1-one in good yield. The amino ketones were converted to the corresponding 7-haloindanone or the 8-halotetralone. Another method to prepare 7-haloindan-1-ones was completed by a cyclization of 3-chloro-1-(2-halophenyl)propan-1-one under Friedel-Crafts conditions to produce the product in gram quantity.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.